Anoop is currently working at Columbia University Medical Center. Prior to this, he managed the IP portfolio at AgaMatrix, a company that makes blood glucose measurement devices for diabetics. Prior to that, he worked at Global Prior Art, an IP consulting company, where is jointly led the medical/surgical device group. His work included IP landscape development to assist in client’s strategic, technical and legal decision making; primarily focusing on minimally invasive cardiothoracic, orthopedic and GI surgery. While at MIT, he was a runner up at the $50K Entrepreneurship Competition, the President of a Cultural group and a Math tutor for a SAT outreach program. He was selected to be a 2008 Fellow in the Startup Leadership Program in Boston. He holds an MS from School of Engineering at MIT, and clinical training and research training from KMC, Mangalore and All India Institute of Medical Sciences (AIIMS), India. All along, his research work in computational biology and medicine was supported by several fellowships & scholarships.

Fellow since

April Effort joined the Technology Development Office at Boston University in November 2007. Prior to joining BU, she worked at the University of Michigan with the Coulter Foundation’s Translational Research Program in Biomedical Engineering. There she helped develop commercialization strategies including market, regulatory and intellectual property assessments for medical devices. In addition to her work with the Coulter program, Ms. Effort has worked as an independent consultant for Arboretum Ventures and several life science start-up companies. As Associate Director of Business Development, she manages Boston University’s portfolio of Life Science inventions along with the Technology Analyst Program. Ms. Effort is a graduate of the University of Michigan where she earned a Master of Science in Molecular, Cellular and Developmental Biology as well as a Bachelor of Science in Cellular and Molecular Biology. In addition to seven years of laboratory research, Ms. Effort also served as a science reporter for the Michigan Daily.

Fellow since

David Kolesky is a Ph.D. candidate at Harvard University, School of Engineering and Applied Sciences. He has previously worked as a Research Assistant at SinPot Research Group, Engineering Freshman Transition Program, and Goldberg Research Group at the University of Florida. He is an expert in Materials Science, Scanning Electronic Microscopy and Nanomaterials. David was awarded the Graduate Prize at the National Collegiate Inventor Competition held by the United States Patent Office. He holds a degree in Materials Science and Engineering and a Ph.D. in Materials Science. He is 2015 Fellow in the Startup Leadership Program in Boston.

Fellow since

David Kolesky is a Ph.D. candidate at Harvard University, School of Engineering and Applied Sciences. He has previously worked as a Research Assistant at SinPot Research Group, Engineering Freshman Transition Program, and Goldberg Research Group at the University of Florida. He is an expert in Materials Science, Scanning Electronic Microscopy and Nanomaterials. David was awarded the Graduate Prize at the National Collegiate Inventor Competition held by the United States Patent Office. He holds a degree in Materials Science and Engineering and a Ph.D. in Materials Science. He is 2015 Fellow in the Startup Leadership Program in Boston.

Fellow since

Kathryn is a leading entrepreneur and Scientist.

Fellow since

Public Health Professor, Researcher and Pilates/Barre instructor

Fellow since

Kerry Mahon is the Manager of Scientific Development at Stemgent, Inc., a company that is pioneering new methods of cellular reprogramming. He joined Stemgent as one of the first scientific hires at the outset of the company in 2008 and continues to support R&D while coordinating new technology evaluation, partnerships, and licensing activities. Kerry completed his postdoctoral studies with Prof. Robert Langer and Prof. Dan Anderson at the Massachusetts Institute of Technology where he engineered new materials for the therapeutic delivery of siRNA, improving delivery efficiency in non-human primates by orders of magnitude over previously published methods. As a graduate student at Boston College, he was awarded a fellowship in Chemical Biology and completed his dissertation under the direction of Prof. Shana Kelley. There, his research focused on the generation and application of novel peptide conjugates for the purposes of studying amino acid-DNA interactions, subcellular localization of small molecules, and cellular responses to oxidative stress. Kerry has consulted for various early stage startups and also held positions at Pfizer, Inc. working in scale-up chemical synthesis and process development. He is an author on ten peer reviewed publications and named inventor on four patents. Kerry is a 2013 Fellow in the Startup Leadership Program in Boston.

Fellow since

Life scientist turned entrepreneur

Fellow since

Fellow since

Sameer Sabir is a co-founder and President of MoMelan Technologies which was acquired by Kinetic Concepts. Sameer is a recent graduate of the Harvard-MIT Biomedical Enterprise Program (BEP), which consists of an MBA from the MIT Sloan School of Management, and an MS from the Harvard-MIT Division of Health Sciences and Technology (HST). During his time on the BEP program, Sameer focused his educational and extracurricular pursuits on entrepreneurship in the life sciences, as well as supplementing his scientific knowledge through taking a number of classes at the Harvard Medical School. He held several teaching assistant and leadership positions, including lead organizer of both the MIT Venture Capital and Private Equity Conference and the MIT Venture Capital Competition. Prior to the BEP program, Sameer was a co-founder and Director of Cinnabar Consulting. Cinnabar Consulting focused on helping early-stage life sciences companies in Scandinavia conduct business and corporate development activities in the USA. The operating model was to engage clients on a long-term basis and integrate into the operating team, which Sameer successfully achieved with his clients. Prior to Cinnabar Consulting, Sameer spent three years in life sciences investment banking with Commerzbank Securities and JPMorgan, focused on working with early stage life sciences companies. Sameer completed his undergraduate studies at University College London (UCL) where he took a BS.c degree in Immunology.

Fellow since

Sanjay is Medical Director of Neurology and Clinical Development at Genzyme and was a Research Fellow at the Children’s Hospital and Harvard Medical School. He has trained as a physician-scientist, and has published several research articles on neurobiology, neurology, bioinformatics and life sciences in leading journals. He has received awards and honors for excellence in research, and has been invited for technical presentations at national meetings. He was selected to be a 2007 Founding Fellow in the Startup Leadership Program in Boston. He is interested in the application of interdisciplinary knowledge resources towards identifying and executing innovative ideas towards improving accessibility to novel therapeutics and devices. An excellent communicator, with experience as a healthcare professional, he has effective problem-solving and organizational skills. Sanjay is passionate about application of translational technology solutions to healthcare industry.

Fellow since

Seth is a healthcare strategy consultant at Clearview Partners. Prior to this he was a consultant at Health Advances, LLC. He is an expert at assisting pharmaceutical, biotechnology, and medical device companies with product commercialization, market assessment, portfolio prioritization, and technology valuation. Prior to his work as a consultant, Seth received his PhD in Biology at the Massachusetts Institute of Technology. As part of his PhD, he created the first specific and controllable mouse model of human osteosarcoma to further the understanding of the disease and catalyze the development of new cancer therapies. Seth has also been a business development intern for PureTech Ventures, a venture firm committed to transforming breakthrough technologies into leading edge firms, and for BioScale, a Boston start-up developing nanotechnology for the identification and differentiation of chemical and biological materials. Seth graduated with a BS in Biochemistry and Economics from Rutgers University, where he was the leader of several undergraduate organizations. In his spare time he is a resident tutor for MIT undergraduates and enjoys playing several intramural sports, cooking, reading, and traveling to foreign countries.

Fellow since

Shinichiro Fuse, Director Business Development, Bluebird Bio. Shin is the Principal at MPM Capital. He is also an contributing writer for Nikkei Biotech, the leading biotech business journal in Japan. Prior to joining bluebird, he was an Engagement Manager in the Corporate Development team at Campbell Alliance, a life science consultancy. Prior to Campbell, he was an Associate at PureTech Ventures, where he was on the founding team of Vedanta Biosciences (a microbiome company) and Mandara Sciences (nutrition). He completed his Ph.D. (Microbiology & Immunology) from Dartmouth College and was an Albert J. Ryan Scholar. He also holds an M.S. from University of Tokyo (Medical Sciences) and B.E. from Keio University (Chemistry), Japan. He is a 2012 Boston Fellow and was the Global Lead for SLP's Education Team from 2013-2014.

Fellow since

Weijie Poh is the Co-Founder of PathoVax LLC, a biotechnology startup commercializing a breakthrough Human Papillomavirus (HPV) vaccine developed at a prestigious research institution in Baltimore, Maryland. Prior to PathoVax, he worked at the Agency for Science, Technology and Research, where he was a Research Officer. Weijie has also worked at Vector BioLabs, Inc, and was a Infantry Training Officer (Lieutenant) for the Singapore Armed Forces. He is an expert in Molecular Biology,Cell and Biotechnology. He holds a degree in Engineering and Applied Sciences and Life Science (Concentration in Cell and Molecular Biology) and a Ph.D. in Pathobiology. He is 2015 Fellow in the Startup Leadership Program in Boston.

Fellow since

Will Adams is the Chief Scientific Officer and Co-founder at Riparian Pharmaceuticals, Inc. He has a Ph.D. from the Harvard School of Engineering and Applied Sciences. Will graduated cum laude from Harvard University with a B.S. degree in Engineering Sciences. He was selected to be a 2010 Fellow in the Startup Leadership Program in Boston. Will participated as an intern within the Cancer Bioscience division of AstraZeneca Pharmaceuticals and later received an M.S. in Applied Mathematics from Harvard University. He is interested in developing more sophisticated assays for higher fidelity preclinical drug testing.

Fellow since